Effects of aurothioglucose and auranofin on radiographic progression in rheumatoid arthritis.

Abstract

Radiographic films of 40 patients participating in a single centre patient blind study of auranofin versus aurothioglucose were evaluated in a random order by one reader. The two treatment groups were comparable with respect to number of erosions and total radiographic score at the start of the study. Only in the auranofin-treated patients was a statistically significant increase in the mean number of new erosions (p less than 0.001 at 6 months and p less than 0.01 at 12 months treatment, paired t-test) as well as in the total radiographic score (p less than 0.01 at 6 and 12 months treatment, paired t-test) observed. Results of this study confirm that parenteral gold compounds do retard radiographic progression of joint destruction in the treatment of rheumatoid arthritis. The effects on radiographic progression shown in this study are in agreement with other reports which, based on clinical and biochemical parameters, have shown that auranofin is somewhat less effective than the injectible gold salts.

• Authors: P L Van Riel, A Larsen, L B Van de Putte, F W Gribnau
• Journal: Clinical rheumatology (Clin Rheumatol) Vol. 5 Issue 3 Pg. 359-64 (Sep 1986) ISSN: 0770-3198 [Print] Germany
• PMID: 3096626 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Aurothioglucose
• Auranofin
• Gold

Topics

• Adult
• Aged
• Arthritis, Rheumatoid (diagnostic imaging, drug therapy)
• Auranofin (administration & dosage, therapeutic use)
• Aurothioglucose (administration & dosage, therapeutic use)
• Clinical Trials as Topic
• Drug Administration Schedule
• Female
• Gold (therapeutic use)
• Humans
• Male
• Middle Aged
• Radiography
• Random Allocation
• Time Factors